Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on LYS-SAF302 received as planned on July 2, 2020, with no change to expected regulatory timelines Paris, France — 24 July 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS)…

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations Paris, France — 01 July 2020 — Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered into a collaborative research agreement with Yeda Research and…

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held its ordinary annual and extraordinary general meeting of shareholders on June 26, 2020, in closed session, which was chaired by Karen Aiach, Chairman of the Board of directors and chief executive officer, without the physical presence of the shareholders. With…

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that, following discussions with the U.S. Food and Drug Administration (FDA), a clinical hold was issued for the clinical trial AAVance (NCT03612869), a global Phase 2/3 clinical…

Lyon and Paris, France, May 26, 2020 – Novasep, a leading supplier of services and technologies for the life sciences industry, and Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the signature of an agreement for the development and manufacturing of LYS- GM101, an…

Paris, France — 20 May 2020 at 06:00pm CEST— Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, informs its shareholders that its annual ordinary and extraordinary general meeting will be held behind closed doors, without the physical attendance by shareholders, on June 26, 2020 at 09:00am…

2020 American Society of Gene & Cell Therapy Annual (ASGCT) virtual Meeting European Forum for Good Clinical Practice (EFGCP) Webinar National Tay Sachs and Associated Diseases (NTSAD) Virtual 2020 Family Conference Paris, France — 14 May 2020 at 08:00am CEST — Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous…

Paris, France — 13 May 2020 at 06:00pm CEST — Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that Kepler Cheuvreux, a leading independent European financial services company specialized in research, execution and advisory services, has initiated its equity research coverage with a report…

PARIS, France – 30 April 2020 – Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the filing of its 2019 Universal Registration Document (URD) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (AMF). This 2019 Registration…